期刊文献+

银灵通胶囊减少人肝细胞系-5细胞的脂肪积聚作用及机制研究

Yinlingtong capsules reduced the accumulation of fat in HHL-5 hepatocytes
原文传递
导出
摘要 目的观察银灵通胶囊对肝细胞系(HHL).5细胞内甘油三酯含量、脂肪酸的氧化水平以及在脂肪氧化过程中起重要作用的代谢酶肉碱脂酰转移酶.1β(CPT-1β)、乙酰辅酶A羧化酶.[3(ACC-β)的影响。方法检测在不同剂量银灵通胶囊水溶物作用下人HHL-5细胞内甘油三酯含量、脂肪酸氧化水平,用Q-PCR检测银灵通处理HHL.5细胞中CPT-1β、ACC.B的mRNA水平。结果银灵通胶囊可降低HHL-5细胞内的甘油三酯含量,与对照组比较,银灵通胶囊溶液0.5、l、2mg/ml剂量组分别降低9.5%、14.3%、19.4%),HHL-5细胞脂肪酸氧化水平分别增加4.3%、6.9%和11.2%,并呈一定的剂量效应关系,但对CPT-1β、ACC.B没有影响。结论银灵通胶囊可通过增强HHL-5细胞脂肪酸氧化水平减少HHL-5细胞的脂肪积聚。 Objective To study the effects of the Yinlingtong capsules on intracellular triglyceride, fatty acid oxidation levels and CPT-1β/ACC-β in HHL-5 cells. Methods After treated HHL-5 cells with different doses Yinlingtong capsules, intracellular triglyceride content and the fatty acid oxidation level were detected by the kits. The CPT-1β and ACC-β mRNA levels were detected by Q-PCR. Results Yinlingtong capsules could reduce triglyceride content (compared with the control group, triglyceride content of 0.5, 1 and 2 mg/ml dose group were reduced by 9.5%, 14.3% and 19.4%, respectively), enhance the level of fatty acid oxidation by a dose-response relationship (compared with the control group, the level of fatty acid oxidation of 0.5, 1 and 2 mg/ml dose group were increased 4.3%, 6.9% and 11.2%, respectively), but could not affect the CPT-1β and ACC-β mRNA levels. Conclusion Yinlingtong capsules reduced the accumulation of fat in HHL-5 hepatocytes, and the specific impact mechanism needs to be further explored.
出处 《国际中医中药杂志》 2013年第3期225-227,共3页 International Journal of Traditional Chinese Medicine
关键词 银灵通胶囊 甘油三酯含量 脂肪酸氧化水平 肉碱脂酰转移酶-1β 乙酰辅酶A羧化酶-β Triglycorido: Fatty acid oxidation level CPT-Iβ ACC-β
  • 相关文献

参考文献7

  • 1郭宏,许传芬,郭冬.非酒精性脂肪肝患者肝损害程度与代谢综合征各组分的关系[J].中国医药,2010,5(12):1139-1141. 被引量:13
  • 2孙梦颖,梁敬钰,冯煦,董云发,印敏,陈雨.三萜酚酸酯类化合物的研究进展[J].天然产物研究与开发,2011,23(2):369-373. 被引量:1
  • 3陈佳,谢作权,叶赛,王珂,王世东,张庆华.银杏叶提取物GBE50对HepG2细胞甘油三酯代谢的影响[J].中国药理学通报,2010,26(7):961-964. 被引量:8
  • 4DjouadiF, Bonnefont JP, MunnichA, et al. Characterization offatty acid oxidation in human muscle mitochondria andmyoblasts. Mol Genet Metab,2003,78 (2): 112-118.
  • 5Takeo Iwata. Hisaaki Taniguchi,Masamichi Kuwajima, et al.The Action of D-Dopachrome Tautomerase as an Adipokine inAdipocyte Lipid Metabolism. PLoS One,2012,7(3): 402-415.
  • 6Wamke 1? Goralczyk R? Fuhrer E? et al. Dietary constituentsreduce lipid accumulation in murine C3H10 T1/2 adipocytes: Anovel fluorescent method to quantify fat droplets. NutrMetab(Lond), 2011’ 8 (1): 30-43.
  • 7Chen ZP, Stephens TJ, Murthy S,et al. Effect of exerciseintensity on skeletal muscle AMPK signaling in humans.Diabetes, 20031 52 (9): 2205-2212.

二级参考文献18

  • 1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1515
  • 2杨曙晖.2型糖尿病合并非酒精性脂肪肝与胰岛素抵抗及血脂紊乱关系研究[J].中国基层医药,2006,13(2):191-193. 被引量:9
  • 3Chang-suo LIU Yong CHENG Jin-feng HU Wei ZHANG Nai-hong CHEN Jun-tian ZHANG.Comparison of antioxidant activities between salvianolic acid B and Ginkgo biloba extract(EGb 761)[J].Acta Pharmacologica Sinica,2006,27(9):1137-1145. 被引量:17
  • 4Olynyk JK,Knuiman MW,Divitini ML,et al.Serum alanine aminotransferase,metabolic syndrome,and cardiovascular disease in an Australian population.Am J Gastroenterol,2009,104 (7):1715-1722.
  • 5Cotler SJ,Dhamija MK,Luc BJ,et al.The prevalence and clinical correlates of elevated ALT levels in an urban Chinatown community.J Viral Hepat,2010,17(2):148-152.
  • 6Oda E,Kawai R,Watanabe K,et al.Prevalence of metabolic syndrome increases with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in Japanese men and women.Intern Med,2009,48 (16):1343-1350.
  • 7Sub SY,Choi SE,Ahn HY,et al.The association between normal alanine aminotransferase levels and the metabolic syndrome:2005Korean National Health and Nutrition Examination Survey.Metabolism,2009,58 (12):1731-1736.
  • 8Hsieh MH,Ho CK,Hou NJ,et al.Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwan Residents adults without chronic hepatitis B or C.Int J Obes (Lond),2009,33(11):1309-1317.
  • 9Goessling W,Massaro JM,Vasan RS,et al.Aminotransferase levels and 20-year risk of metabolic syndrome,diabetes,and cardiovascular disease.Gastroenterology,2008,135(6):1935-1944.
  • 10Nannipieri M,Gomnzales C,Bladi S,et al.Liver enzymes,the metabolic syndrome,and incident diabetes:the mexico city diabetes study.Diabetes Care,2005,28 (7):1757-1762.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部